Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Lyell Immunopharma Inc
LYELCurrent price
1.1 USD
-0.01 USD (-0.90%)
Last closed
1.1 USD
Company
www.lyell.com
ISIN
US55083R1041
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
340 649 632 USD
Yield for 12 month
-46.34 %
1Y
3Y
5Y
10Y
15Y
LYEL
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California. Address: 201 Haskins Way, South San Francisco, CA, United States, 94080
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
2 USDP/E ratio
–Dividend Yield
–Current Year
+130 000 USD
Last Year
+84 683 000 USD
Current Quarter
+34 000 USD
Last Quarter
+13 000 USD
Current Year
-20 120 000 USD
Last Year
+68 216 001 USD
Current Quarter
+34 000 USD
Last Quarter
-4 888 000 USD
Key Figures LYEL
1 year
3 years
5 years
10 years
EBITDA
-196 600 000 USD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-19.12 %
PEG Ratio
–
Return On Equity TTM
-33.22 %
Wall Street Target Price
2 USD
Revenue TTM
63 000 USD
Book Value
2.07 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
36 %
Dividend Yield
–
Gross Profit TTM
84 683 000 USD
Earnings per share
-0.79 USD
Diluted Eps TTM
-0.79 USD
Most Recent Quarter
III 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics LYEL
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History LYEL
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
–
Payout Ratio
–
Last Split Date
–
Dividend Date
–
Stock Valuation LYEL
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
1938.0921
Price Sales TTM
5407.137
Enterprise Value EBITDA
0.251
Price Book MRQ
0.6393
Financials LYEL
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators LYEL
For 52 weeks
0.85 USD
3.26 USD
50 Day MA
1.23 USD
Shares Short Prior Month
10 657 278
200 Day MA
1.86 USD
Short Ratio
13.91
Shares Short
10 759 090
Short Percent
5.96 %
BeatStart